CD163 and cancer: From 243 patients with traceable sCD163 levels at the time of NAFLD diagnosis, 13 patients had HCC onset and 15 patients died (10 patients had liver-related deaths, 3 patients had cancers of other organs, and two patients had cardiovascular events).